Therapeutics, Early Phase Clinical Trials and Pharmacokinetics-Pharmacodynamics

Lead: Saye Khoo (University of Liverpool)

Hollow fibre infection models are being developed to assess new antiviral compounds.  Clinical protocols are being developed to test experimental therapies for COVID-19.  Clinical trials are supported by GCP bioanalytical capabilites and PK-PD modelling.  Prescribing resources to support clinical trials of experimental COVID therapies have been developed.